NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Ascentage Pharma Group Internat (AAPG) Stock Analysis

Ascentage Pharma Group Internat (AAPG) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

AAPG

$17.62

+$0.25 (+1.47%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare AAPG with… →

AAPG Key Statistics

As of Sep 4, 2026
Trading
Open
$17.70
Previous Close
$17.36
Day's Range
17.60–17.75
52-Week Range
16.23–41.40
Volume
5.10K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.67
Valuation
Market Cap
$1.65B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
2.56
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.35
Financials (FY)
Revenue (FY)
$574.12M−41.46%
Net Income (FY)
−$1.24B
Profit marginThe share of revenue left as profit after all costs and taxes.
−228.54%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
93.39M
1-Year Return
−54.34%
Dividend and dates
Avg Volume
10.37K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

AAPG Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−32.87%
2025+50.98%

As of September 4, 2026.

AAPG Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$574.12M−$1.24B−216.5%
2024$980.65M−$405.43M−41.3%
2023$221.98M−$925.64M−417.0%
2022$209.71M−$882.92M−421.0%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$574.12M$525.18M−$1.20B−$1.24B−216.5%
2024$980.65M$951.57M−$369.73M−$405.43M−41.3%
2023$221.98M$191.44M−$872.64M−$925.64M−417.0%
2022$209.71M$187.71M−$849.81M−$882.92M−421.0%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

AAPG Valuation vs Biotechnology Median

Median of 656 stocks
MetricAAPGBiotechnology medianvs median
P/S ratio2.5615.260.2x the median
Profit margin−228.54%0.00%228.5 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 9 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Ascentage Pharma Group Internat (AAPG) at $1.65B. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 828 employees.

The 52-week range on file runs from $16.23 to $41.40. The most recent close on file for AAPG is $17.62, dated September 4, 2026. That is +$0.25 (+1.47%) against the previous close. The latest close sits 8.53% above that 52-week low.

Financial Health

In fiscal 2025, Ascentage Pharma Group Internat reported revenue of $574.12M. Against the prior fiscal year total of $980.65M, that is a change of −41.46%. The same year closed with a net loss of $1.24B. The reported profit margin is −228.54%. That is 228.5 percentage points below the Biotechnology median of 0%. Trailing earnings per share are −2.35.

Across the 4 fiscal years on file, revenue moves from $209.71M in 2022 to $574.12M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 2.56 times revenue. On price-to-sales that is 0.2 times the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

The trailing one-year price return is −54.34%. The stored price history starts on January 24, 2025, and the total return since then is +1.35%. Beta against the wider market is reported at 0.67. Annualized volatility over the trailing 1 year is 58.3%.

Growth & Income

No dividend is on file for AAPG.

So far in 2026 the price is −32.87%. The record holds one complete calendar year, 2025, which returned +50.98%.

Peer Comparison

Ascentage Pharma Group Internat (AAPG) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Ascentage Pharma Group Internat AAPG $1.65B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Ascentage Pharma Group Internat has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Ascentage Pharma Group Internat

Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small-molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-5918, an orally available and selective embryonic ectoderm development inhibitor. In addition, it is involved in medical research and development; clinical development; clinical trials operations; venture capital investment; rental of buildings; and provision of science and technology promotion services. The company has collaboration relationships with biotechnology and pharmaceutical companies; and research institutions. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.

Visit website →